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Functional diversity of AT2 receptor orthologues in closely re-
lated species.
Background. The most striking feature of life is biodiver-
sity. However, mechanisms of biodiversity remain poorly un-
derstood, as most protein orthologues of different species are
highly homologous in sequence and identical in function. Inter-
estingly, recent evidence has demonstrated heterogeneity for
a G protein-coupled angiotensin II (Ang II) type 2 (AT2) re-
ceptor in both ligand binding and induction of arachidonic acid
(AA) release. The present study investigated the properties of
AT2 receptors in closely related species.
Methods. AT2 receptors cloned from human, rabbit, rat, and
mouse were expressed in Chinese hamster ovary cells (CHO-
K1), African green monkey kidney cells (COS-1), and human
embryonic kidney (HEK)-293 cells and characterized in ligand
binding and signal transductions. Critical residues in rabbit AT2
receptor attributable to heterogeneity were examined using
both gain-of-function and loss-of-function approaches with mu-
tagenesis.
Results. The newly cloned rabbit AT2 receptor exhibits
distinct biochemical and biologic properties compared to its
highly homologous orthologues (91% in overall amino acid se-
quence) of rat, mouse, and human. All these orthologues acti-
vate SH2 domain-containing phosphatase-1 (SHP-1) and show
similar binding affinities for Ang II and AT2-specific ligands
CGP42112A and PD123319. However, reducing agent dithio-
threitol (DTT) inactivates the rabbit orthologue but potentiates
the others in ligand binding, a hallmark of AT2 versus AT1 re-
ceptor subtypes. Most interestingly, rabbit AT2 receptor, but
not the other orthologues, induces AA release in various cell
systems when stimulated by both Ang II and CGP42112A, the
peptide antagonist. Mutagenesis studies and sequence analy-
ses further indicate that residues His106, Asp188, and Thr293 are
responsible for the DTT inactivation and residues Val209 and
Val249 are partially responsible for AA release.
Conclusion. These results deny the coexistence of an addi-
tional AT2 subtype in rabbit proximal tubule cells and demon-
strate for the first time the presence of functional diversity for
closely related Eutherian orthologues of a G protein–coupled
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receptor (GPCR) that are more than 90% homologous in the
amino acid sequence.
The angiotensin II (Ang II) type 2 (AT2) receptor be-
longs to the superfamily of G protein–coupled receptor
(GPCR). It exerts inhibitory actions to counteract the
type 1 Ang II receptor, AT1, in blood pressure regula-
tion and cell growth. In humans and mice, AT2 exists
as a single copy localized on the X chromosome (re-
gion Xq24-q25 and region XA2-A4, respectively) and
contains no intron in its coding region. Thus the ex-
istence of multiple forms of AT2, encoded by several
homologous genes or derived by alternative splicing, is
not possible [1–3]. However, earlier studies from several
independent groups have suggested the presence of het-
erogeneous populations of the AT2 receptor. For exam-
ple, the AT2 receptor in different brain regions exhibited
differential sensitivity to GTPcS [4]. In rabbit proximal
tubule epithelial cells, Dulin et al [5] and Jacobs and Dou-
glas [6] discovered an AT2 population with completely
reduced binding in the presence of dithiothreitol (DTT).
Activation of this population of AT2 receptors induced
arachidonic acid (AA) release in rabbit proximal tubu-
lar epithelial cells, a finding not observed in primary cells
of other species [6]. In N1E-115 murine neuroblastoma
cells, Reagan et al [7] and Yee et al [8] also observed two
biochemically, pharmacologically, and immunologically
different subpopulations of AT2 receptors. These inves-
tigators have therefore suggested the existence of AT2A
and AT2B subtypes to explain the observed heterogeneity
concerning the AT2 receptors.
It is logical to assume that protein orthologues, partic-
ularly orthologues of closely related species, are iden-
tical in function because they are highly homologous
(>90%) in amino acid sequence. AT2 receptors share
>91% amino acid identity and presumably should not be
exceptional. In order to determine whether the hetero-
geneity of the rabbit AT2 (rbAT2) receptor results from
a new subtype of AT2 receptor, we have cloned an AT2
receptor from rabbit proximal tubular epithelial cells to
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examine the structural determinants which contribute to
the unique phenotypic characteristics of this species [5, 6].
We now show that the rbAT2 receptor is a conventional
AT2 receptor orthologue rather than a novel subtype of
the AT2B receptor. However, this rabbit orthologue ex-
hibits functional diversity in biochemical, pharmacologic,
and physiologic properties.
METHODS
Materials
The monoclonal anti-c-myc antibody (clone 9E10)
(Roche, Indianapolis, IN, USA), oligonucleotides
[Sigma-Genosys (The Woodlands, TX, USA) and MWG
Biotech (High Point, NC, USA)], Ang II and [Sar1, Ile8]
Ang II (Bachem, King of Prussia, PA, USA), PD123319
and CGP42112A (RBI), [3H]-AA (NEN Life Science,
Boston, MA, USA), Protein Tyrosine Phosphatase Assay
Kit (Upstate Biotechnologies, Lake Placid, NY, USA),
DTT, and other chemicals (Sigma) were purchased.
125I-[Sar1, Ile8] Ang II (2200 Ci/mmol) was supplied by
Dr. Robert Speth (University of Washington, Pulman,
WA, USA).
DNA cloning, mutagenesis, polymerase chain reaction
(PCR), and expression
The cDNA of rbAT2 was cloned from total RNA iso-
lated from rabbit primary proximal tubule epithelial cells
by reverse transcription (RT)-PCR with degenerate oli-
gonucleotide primer FD1 (GTGGTT/CA/TCACTGTTT
TGTTGTCAAAA) and FD2 (CAGCTGTTGGTGAA
TCCCAG/AGAGGATGGCAAAA), and SMARTTM
RACE cDNA Amplification Kit (ClonTech, Palo Alto,
CA, USA). The cloned cDNA was fully sequenced and
modified for expression in cell lines (1) to contain a con-
sensus Marilyn-Kozak sequence and a unique EcoRI site
at the 5′ end and NotI site at the 3′ end of the gene;
and (2) to encode a decapeptide (EQKLISEEDL) epi-
tope tag for a monoclonal antibody anti-c-myc at the
5′ end after the start codon. The epitope-tagged cDNA
was subcloned into a shuttle vector pcDNA6 (Invitro-
gen, Carlsbad, CA, USA). Identical modification was ap-
plied to rat (rAT2) mouse (mAT2), and human (hAT2)
AT2 genes subcloned into the pcDNA6 vector for expres-
sion. Mutant AT2 receptors were prepared by the restric-
tion fragment-replacement method and the PCR method.
DNA sequence analysis was done to confirm each mu-
tant construct. For expression of receptor proteins, 3 lg
of column (Qiagen, Valencia, CA, USA) purified plas-
mid DNA per 107 cells was used in transfection. CHO-
K1, COS-1, and human embryonic kidney (HEK)-293
cells (ATCC, Manassas, VA, USA), cultured in ATCC-
preferred medium supplemented with 10% fetal bovine
serum (FBS), were transfected by the GenePORTERTM
transfection reagents (GTS, Inc., San Diego, CA, USA).
For PCR detection of intronless AT2 receptors, genomic
DNAs of human, mouse, rat, and rabbit purchased from
ClonTech were used as templates for conventional PCR
with respective sense and antisense primers derived from
known sequences available in the GeneBank.
Southern blot
A DNA fragment probe of 740 bp was prepared by
EcoRI digestion of a TOPO TA vector plasmid DNA
(Invitrogen) that contains a PCR insert of rbAT2 syn-
thesized with primer FD1 and FD2. This DNA probe (20
ng/lL) was labeled with AlkPhos Direct Kit (Amersham,
Piscataway, NJ, USA) following the company’s proto-
col. Genomic DNAs of rabbit, human, rat, and mouse
(ClonTech) were digested with EcoRI and visualized by
chemiluminescent detection with CDP-Star (Amersham)
after gel separation, membrane transfer, and hybridiza-
tion with the labeled probe.
Western blot of receptors expressed in CHO-K1 cells
Postnuclear supernatant of CHO-K1 cells solubilized
in lysis buffer [50 mmol/L Tris-HCl, pH 6.8, 1% CHAPS,
5 mmol/L ethylenediaminetetraacetic acid (EDTA), pH
8.0] containing 50 lg/mL phenylmethylsulfonyl fluoride
(PMSF), 10 lg/mL benzamidine, 10 lg/mL bacitracin, 10
lg/mL leupeptin, and 2 lg/mL aprotinin, was used for
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and Western blotting analysis. Recep-
tor polypeptides were visualized using 1:1000 dilution of
mouse monoclonal anti-c-myc antibody and 1:3000 dilu-
tion of secondary antimouse antibody coupled to per-
oxidase and the enhanced chemiluminescence (ECL)
system (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) as described [9–11].
DTT treatment, ligand binding assay, and AA
release assay
DTT treatment of membrane preparations, saturation
binding, and competitive binding assay were performed
as described earlier [9–11]. AA release was assayed
based on published methods [6] with minor modifications.
Briefly, CHO-K1 cells and transfected CHO-K1 cells cul-
tured in 6-well plates were allowed to grow for 24 hours
before they were labeled with [3H]-AA (0.3 lCi/mL or
10 nmol/L [3H]-AA) overnight. The cells were washed
three times with basal medium (serum-free medium plus
25 mmol/L Hepes, pH 7.5) and then treated with 1.0 mL
basal medium containing Ang II for 15 minutes at 37◦C.
The stimulation was stopped by putting the plates on ice
and the medium was transferred into prechilled appro-
priate tube for centrifugation at 15,600g and at 4◦C count
half the volume (0.5 mL medium) was counted in 5 mL
scintillation tubes. For total cellular radioactivity, cells in
each well were solubilized with 1 mL of 1 mol/L NaOH
and counted in 5 mL scintillation tubes. [3H]-AA released
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into the medium is expressed as percent of the total cel-
lular radioactivity and referred to as fractional release:
fractional [3H]-AA release = (count in the medium/count
in the cells) ∗%.
Immunoprecipitation and SHP-1 activity assay
Twenty-four hours after cotransfection with AT2 and
SHP-1 (kindly provided by M. Thomas, Washington Uni-
versity, St. Louis, MO, USA), CHO-K1 cells were starved
overnight and then stimulated with Ang II for 3 min-
utes. After treatment, cells were rinsed with ice-cold
phosphate-buffered saline (PBS), then solubilized for 30
minutes at 4◦C in lysis buffer (50 mmol/L Tris-HCl, pH
7.5, 1.5% CHAPS, 150 mmol/L NaCl, and 5 mmol/L
EDTA), containing 0.5 mmol/L sodium orthovanadate,
10 lg/mL benzamidine, 10 lg/mL bacitracin, 10 lg/mL
leupeptin, 2 lg/mL aprotinin, and 50 lg/mL PMSF. Af-
ter centrifugation at 15,000g for 15 minutes, the result-
ing supernatant (1 to 1.5 mg of protein) was incubated
for 2 hours at 4◦C with 10 lL of monoclonal anti-SHP-1
antibody prebound to sepharose protein A (Santa Cruz
Biotechnology). The immunocomplexes were washed
five times with washing buffer (identical to the lysis buffer
but without 1.5% CHAPS and 0.5 mmol/L sodium ortho-
vanadate). At the end of washing, the immunocomplexes
were resuspended in PTPase buffer [50 mmol/L Tris-HCl,
pH 7.0, 1 mg/mL bovine serum albumin (BSA), and 5
mmol/L DTT]. The PTP activity was assayed by mea-
suring the release of inorganic phosphate from phospho-
peptides based on a malachite green detection system [12]
using the PTPase Assay Kit (Upstate Biotechnology) fol-
lowing the company’s protocol.
Statistical analysis
The results are expressed as the mean ± SEM of two
to five independent determinations. The significance of
measured values was evaluated with an unpaired Student
t test.
RESULTS
Cloning and sequence analysis of an rbAT2 receptor
To determine whether an AT2B subtype exists in the
rabbit kidney cortex and to elucidate the mechanism of
functional diversity of the renal AT2, we cloned the re-
nal AT2 from rabbit kidney cortex (GeneBank, acces-
sion number AF451328). The polypeptide encoded by
the open reading frame consists of 363 amino acids and
shares a high identity of 91% in overall amino acid se-
quence with its human, rat, and mouse AT2 orthologues
(Fig. 1). This high degree of identity falls within the range
for many other protein orthologues including AT1. The
rbAT2 bears all the structural features of the other AT2
orthologues, including seven transmembrane helices and
four cysteine residues located on the extracellular do-
mains. Sequence alignment identified 19 nonconserved
unique residues for rbAT2 when compared to the hu-
man, rat, and mouse orthologues as shown in Figure 1.
Of these 19 residues, 63.2% located in the N-terminal
and transmembrane I, 10.5% in the transmembranes II
to VII, 10.5% in intracellular domains, and 15.8% in ex-
tracellular domains. In addition, the rbAT2 is short of one
potential N-glycosylation site at Asn24 due to the Phe26
substitution in comparison to the other three orthologues.
The rbAT2 is a conventional AT2 orthologue
PCR using rabbit genomic DNA as templates for am-
plification produced a single band of 1.1 kb (data not
shown). This PCR product is identical to the complete
coding region of the rbAT2 gene as confirmed by DNA se-
quencing, indicating its intronless property of the coding
region similar to the other three orthologues. Southern
blot using an 800 bp fragment of rbAT2 DNA as probe
detected a single band, suggesting little possibility of ex-
istence of other AT2 subtypes (Fig. 2). Thus, we conclude
that this rbAT2 is an orthologue of the human, rat, and
mouse AT2, rather than a new AT2B subtype.
Identical ligand binding affinity but distinct DTT sensi-
tivity of rbAT2
The rbAT2 must reproduce the similar function
observed in rabbit kidney cortex in a surrogate cell
system since the data above has ruled out the presence
of AT2 heterogeneity [5, 6]. To first examine the ligand
binding property, expression of rabbit, human, rat,
and mouse AT2 orthologues in COS-1 and CHO-K1
cell lines was verified by Western blot [9–11] with
a specific anti-c-myc antibody which recognizes the
c-myc tag at the N-terminal of the receptors (Fig. 3).
Saturation binding of 125I-[Sar1, Ile8] Ang II and com-
petitive binding of 125I-[Sar1, Ile8] Ang II against [Sar1,
Ile8] Ang II, and AT2-specific ligand CGP42112A and
PD123319 were applied to the four AT2 orthologues,
respectively [9–11]. Table 1 summarizes the data and
shows little difference in binding affinity among four
orthologues in the presence or absence of DTT treat-
ment. Analogous to the human, rat, and mouse AT2, the
rabbit orthologue also exhibits an eightfold increase in
affinity in the presence of 5 mmol/L DTT [9]. However,
distinct from the human, rat, and mouse AT2, the rabbit
orthologue shows an 80% (4.8-fold) decrease in Bmax
in the presence of 5 mmol/L DTT as compared to
no DTT treatment. As a result, the binding curve of
125I-[Sar1, Ile8] Ang II for rbAT2 is in sharp contrast to
the curves for the human, rat, and mouse orthologues
(Fig. 4). Of 19 nonconserved unique residues, His106,
Asp188, and Thr293 are the amino acids that locate in
the extracellular domains of the rbAT2. Deletion of
the N-terminal (the first 33 amino acids) of the rbAT2
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Fig. 1. ClustalW alignment of angiotensin II (Ang II) type 2 (AT2) receptor orthologues of rat, mouse, human, and rabbit (GeneBank accession
number AF451328). Putative transmembrane (TM) domains I to VII are underlined. Nineteen nonconserved unique residues for rabbit AT2 in
comparison to rat, mouse, and human orthologues (∗). Of the 19 residues, 12 residues (63.2%) are located in the N-terminal and TM I, three
residues (15.8%) in extracellular domains, two residues (10.5%) in TM II to VII, and two residues (10.5%) in intracellular domains. Four potential
glycosylation sites (NxS/T) present in all four orthologues (). At Asn24 shows the potential glycosylation site present in all three orthologues
but not in the rabbit AT2 (NxF) (). Four highly conserved Cys residues that form two disulfide bonds of Cys35-Cys290 and Cys117-Cys195 in AT2
receptor (§). Computer software: MacVector (Oxford Molecular, Inc.).
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Fig. 2. Southern blot detection of angiotensin II (Ang II) type 2 (AT2)
receptor gene subtypes or isoforms. Plasmid, rat AT2 receptor cDNA
subcloned in pcDNA3 vector.
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Fig. 3. Western blot detection of angiotensin II (Ang II) type 2 (AT2)
receptor orthologues expressed in CHO-K1 cells with specific anti-c-
myc antibody. Abbreviations are: rbAT2, rabbit AT2; rAT2, rat AT2;
mAT2, mouse AT2; hAT2, human AT2.
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Fig. 4. Effect of varying concentrations of dithiothreitol (DTT) on 125I-
[Sar1, Ile8] angiotensin II (Ang II) binding to Ang II type 2 (AT2)
receptor orthologues. The specific binding of 125I-[Sar1, Ile8] Ang II
in each sample was adjusted to be <10 ± 1% (≈20,000) of total input
cpm without any treatment. This value is represented as 100%. Samples
were first exposed to DTT at 22◦C for 20 min and then the ligand was
added. Abbreviations are: rbAT2, rabbit AT2; rAT2, rat AT2; mAT2,
mouse AT2; hAT2, human AT2.
(mutant rbAT2N) does not alter the property of DTT in-
activation (Table 1).
All four AT2 orthologues activate SHP-1 but only the
rbAT2 mediates AA release
Activation of an AT2 by Ang II in rabbit kidney ep-
ithelial cells has been shown to induce AA release [5, 6].
Consistently, Ang II stimulation induced marked [3H]-
AA release in CHO-K1 cells transiently transfected
with rbAT2. The addition of an AT2-specific antagonist
PD123319 inhibited the [3H]-AA release. However, [3H]-
AA release was not observed in CHO-K1 cells transiently
transfected with human, rat, and mouse AT2 orthologues
(Fig. 5). These results were reproduced using COS-1 and
HEK-293 cell lines (data not shown).
Ang II stimulation of human AT2 in CHO-K1 and
PC12 cells has been shown to activate SHP-1, a SH2
domain-containing phosphatase [13, 14]. Contrary to the
[3H]-AA release, all four AT2 orthologues activated
SHP-1 with no appreciable differences in CHO-K1 cells
as detected by tyrosine phosphatase assay of SHP-1–
specific immunoprecipitates (Fig. 6).
Key residues determine AA release
The most critical regions directly specifying G protein
selectivity are the cytoloop 2 and 3 domains [15]. To un-
derstand the molecular mechanism of rbAT2-mediated
[3H]-AA release, rbAT2 mutant, V209A-V249I, and
its rat reciprocal counterpart, A209V-I249V, were con-
structed simply by switching a DNA fragment between
rabbit and rat wild-type AT2 receptors. The two mu-
tants maintained all the binding properties of their own
wild-type (data not shown). The mutant V209A-V249I
of rbAT2 lost 64% activity in [3H]-AA release whereas
the mutant A209V-I249V of rat AT2 gained 30% activity
(Fig. 5), indicating that Val209 and Val249 of the rbAT2 con-
tribute to [3H]-AA release. Substitution of amino acid in
the N-terminus of AT2 receptor shows no effect on AA
release since rbAT2N maintains full activity (Fig. 5).
Variations in potential phosphorylation sites
Phosphorylation is a fundamental mechanism in reg-
ulation of GPCR functions. We analyzed potential sites
of Ser, Thr, and Tyr phosphorylation for these four or-
thologues by NetPhos 2.0 and detected several unique
sites for each orthologue as summarized in Table 2 [16].
This suggests another potential mechanism to understand
how substitution of a seemingly noncritical amino acid in
the microenvironment could impose profound impact on
receptor function through alteration of phosphorylation.
DISCUSSION
Almost all receptors including the AT2 may act differ-
ently in different locations of the same species. This ex-
citing and complex phenomenon is beyond the sphere of
this study because this type of difference displayed by an
identical receptor is unlikely caused by a receptor itself.
In contrast, this study deals with functional differences
caused by a receptor itself due to structural differences.
In the AT2 receptor, most variations (∼50%) of amino
acids are located within the short N-terminal region of the
receptor orthologues (Fig. 1). However, these variations
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Table 1. Binding affinity and Bmax of angiotensin II (Ang II) type 2 (AT2)
[Sar1, Ile8] Ang II(Ki, nM) CGP42112A(Ki, nM) PD123319(Ki, nM) Bmax (pmol/mg)
DTT DTT DTT DTT
Control (5 mmol/L) -fold Control (5 mmol/L) -fold Control (5 mmol/L) -fold Control (5 mmol/L) -fold
rbAT2 0.89 ± 0.15 0.09 ± 0.02 9.89 0.61 ± 0.13 0.07 ± 0.01 8.71 17.7 ± 2.2 2.4 ± 0.43 7.38 4.05 ± 0.35 0.85 ± 0.38 4.765
rAT2 0.82 ± 0.14 0.08 ± 0.01 10.3 0.65 ± 0.11 0.07 ± 0.01 9.29 17.2 ± 2.5 2.1 ± 0.37 8.19 4.11 ± 0.32 3.95 ± 0.34 1.041
mAT2 0.83 ± 0.12 0.08 ± 0.01 10.4 0.63 ± 0.10 0.08 ± 0.01 7.88 18.4 ± 2.8 2.5 ± 0.31 7.36 4.08 ± 0.36 4.09 ± 0.41 0.998
hAT2 0.87 ± 0.11 0.09 ± 0.01 9.67 0.57 ± 0.09 0.07 ± 0.01 8.14 16.7 ± 2.6 2.3 ± 0.36 7.26 3.93 ± 0.33 3.91 ± 0.37 0.995
rbAT2N 2.98 ± 0.76 0.11 ± 0.02 27.1 0.69 ± 0.12 0.08 ± 0.01 8.63 17.6 ± 2.3 2.3 ± 0.38 7.69 3.78 ± 0.32 0.62 ± 0.35 6.096
Abbreviations are: DTT, dithiothreital; rbAT2, rabbit AT2; rAT2, rat AT2; mAT2; mouse AT2; hAT2; humanAT2.
Cell membranes were pretreated with and without 5 mmol/L DTT at 22◦C for 20 minutes. The rbAT2N is a rbAT2 mutant with deletion of the first 33 amino acids.
This mutant is very similar to the wild-type rbAT2 except for a reduced binding affinity (3.3-fold) for [Sar1 Ile8] Ang II in the absence of DTT treatment. Data represent
results of three or more experiments of binding isotherms followed by Scatchard analysis. Results are presented as mean ± sen.
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Fig. 5. [3H]-arachidonic acid (AA) release induced by angiotensin II
(Ang II) stimulation of mock-transfected and Ang II type 2 (AT2)-
transfected CHO-K1 cells. The mutant V209A-V249I of rabbit AT2
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Abbreviations are: mAT2, mouse AT2; hAT2, human AT2.
reveal little functional diversity in the study as demon-
strated by the rbAT2N with comparison to the wild-type
rbAT2. Thus, we speculate that the amino acid sequence
in the N-terminus may specify the species signal or origin
for the AT2 receptors.
Substitution of His106, Asp188, and Thr293 in the rbAT2
may increase the DTT accessibility to the highly con-
served disulfide bond of Cys117-Cys195 of the receptor
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Fig. 6. SH2 domain-containing phosphatase-1 (SHP-1) activity in-
duced by angiotensin II (Ang II) (100 nmol/L) stimulation of CHO-K1
cells cotransfected with SHP-1 and Ang II type 2 (AT2) receptor ortho-
logues. Abbreviations are: rbAT2, rabbit AT2; rAT2, rat AT2; mAT2,
mouse AT2; hAT2, human AT2.
[9]. Breakage of this disulfide bond in a GPCR results
in complete loss of function due to misfolding [9].
Residue Ala63 located in the cytoloop 1 also may di-
rectly attribute to AA release [12] since the gain-of-
function and loss-of-function were not equivalent and not
close to 100%. In addition, residues located in the trans-
membrane domains (Tyr37, Gln43, Arg48, Phe53, Ser59, and
Val94) may indirectly and collectively affect G protein
coupling selectivity and efficiency through alteration of
critical GPCR conformations [10, 11, 15].
Although properties of ligand binding to AT2 recep-
tors are well established, the full impact on biologic func-
tion(s) and many other properties of the AT2 receptor
remain elusive. This report on one hand explains why
two types of AT2 receptors were detected previously in
the presence and absence of DTT and indicates that no
AT2 subtype receptors exist in rabbit. The previously ob-
served heterogeneity likely resulted from functional di-
versity. However, it is unclear to us at this stage as to what
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Table 2. Phosphorylation sites of angiotensin II (Ang II) type 2
(AT2) orthologues
rbAT2 rAT2 mAT2 hAT2
Ser6∗ NA x x NA
Ser16∗ NA — x —
Ser36∗ x x x x
Ser40∗ x NA x x
Ser145 x x x x
Ser152 x x x x
Ser346 x NA NA x
Ser348 x x x x
Ser352 x x NA x
Ser353 x x x x
Ser354 x x x x
Thr10∗ NA x x —
Tyr143 x x x x
Tyr189a x — — —
Tyr204a x x x x
Total 12(61) 11(63) 12(63) 11(64)
Abbreviations are: rbAT2, rabbit AT2; rAT2, rat AT2; mAT2, mouse AT2;
hAT2, human AT2.
Potential sites of Ser, Thr and Tyr phosphorylation are predicted by NetPhos
2.0 Internet program(16).
X is the potential phosphorylation site is predicted; — is no potential
phosphorylation is predicted; and NA is residue not available. aLocated in the
extracellular domains and extracellular half region of transmembrane domains.
The superscript numbers in the brackets represent the total numbers of Ser,
Thr, and Tyr residues available in the receptor orthologues, respectively.
the physiologic significance of the functional diversity,
predominantly, the DTT sensitivity and induction of AA
release can be. Given the observation that redox potential
can also serve as an important regulation mechanism for
protein activation [17, 18], the distinct DTT property of
rabbit AT2 may provide an alternative mechanism for re-
ceptor activation under pathologic states in which redox
potential is altered. However, it is unclear whether the
cell surface receptor AT2 could be influenced intracellu-
larly by the redox potential during the receptor folding,
maturation, and intracellular trafficking since alteration
of redox potential may occur only inside the cell under
physiologic conditions. Under pathologic conditions such
as myocardial infarction, injury, and inflammation, inter-
stitial redox potential may change significantly. Interest-
ingly, the expressions of AT2 receptors were increased
significantly under these pathologic conditions [1–3].
For protein orthologues with significantly less amino
acid identity, functional diversity has been observed. For
example, the human P2 nucleotide receptor P2X7 binds
to ligand KN-62 and KN-04 whereas rat P2X7 (80% iden-
tity) does not [19]. Mammalian AT1 orthologues (human,
rat, mouse, rabbit, etc., with 95% identity) bind to AT1-
specific ligand losartan, whereas amphibian AT1 recep-
tor (Xenopus, 60% identity) does not [20]. Functional
diversity for protein orthologues with amino acid iden-
tity greater than 90% is rare. The collective or synergistic
effect of limited substitutions of seemingly unimportant
amino acids may play a more important role in functional
diversity than previously appreciated. Variation of phos-
phorylation sites (as shown in Table 2), conformation of
interaction motifs, and accessibility of interaction motif
or domains are potential factors that also determine func-
tional diversity of receptor orthologues.
For GPCRs, Granneman, Lahners, and Chaudhry [21]
and Granneman Lahners, and Rao [22] reported dif-
ferent pharmacologic profiles between human and rat
b 3-adrenergic receptors. However, the human and rat b 3-
adrenergic receptors share only 79% identity in amino
acid sequence. Mallee et al [23] also documented dif-
ferent species selectivity for nonpeptide antagonists be-
tween human and rat CGRP receptors, an atypical
GPCR in that it requires heterodimerization of CRLR,
a classic seven transmembrane receptor, with the acces-
sory protein RAMP1. However, this difference resulted
from variations of a single residue at position 74 in the
accessory protein RAMP1 that bears 71% homology.
Replacement of this single residue in CGRP receptor pro-
duced little difference in binding to the native peptide
ligand CGRP. The mechanism of an accessory protein-
mediated modulation in receptor pharmacology could be
very different and complex. One may find different phar-
macologic properties for receptor orthologues of closely
related species. However, differences in intrinsic proper-
ties such as signal transduction are not documented.
The mechanism of biodiversity is largely unknown.
Functional diversity of many individual genes may serve
as one of the potential mechanisms. Most recently, iden-
tification of the human-specific gene family provided
another exciting potential mechanism to explain what
makes chimpanzees and humans different [24].
Biodiversity is an intriguing concept for biomedical re-
search. Mouse, rat, and rabbit are the most widely used
animal species for human study in biomedicine. For ex-
ample, more and more genetically modified animals with
diseases or disorders are used to study gene functions,
produce gene products, conduct gene therapies, and test
new drugs. Animal genes and cells are widely used as ob-
jects or tools of molecular and cellular studies on funda-
mental mechanisms such as protein-protein interaction
and signal transduction. In many studies, species com-
patibility is not considered for heterologous expression
of a gene in cells or even animals. These have posed
an unprecedented challenge to biomedical scientists be-
cause in many cases results from one study are not com-
pletely reproducible in another application. In the field
of GPCR research, the presence of multiple subtypes of
many receptors with yet no detectable difference in func-
tion represents just another example of the current chal-
lenge [25]. Elucidation of functional diversity for these
GPCR subtypes would improve drug efficacy and reduce
side effects. In the field of evolution and comparative bi-
ology, phylogenetic methods based on one-dimensional
sequence analysis may not be accurate in predicting the
1738 Feng et al: Functional diversity of AT2
evolutionary positions of branching orders of organisms
[26] if functional diversity as reported here is not consid-
ered.
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